Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHAR359 > Oncology 4 > Flashcards

Oncology 4 Flashcards

(49 cards)

Start Studying
1
Q

What are the five pillars of cancer care?

A

radiotherapy
surgery
traditional chemotherapy
precision therapy
immunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which pillar of cancer care has a durable response in patients who respond to therapy?

A

immunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is immuno-oncology?

A

development and delivery of therapies that improve immune response against cancer
-provides immune system with tools to recognize tumours and strengthen tumour attack

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the goal of immuno-oncology?

A

restore or enhance anti-tumour immune responses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the side effects of immuno-oncology agents related to?

A

immune-related and can affect any organ
-may include colitis/diarrhea, rash, hepatitis, endocrinopathies, uveitis, nephritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the types of IO therapy?

A

monoclonal antibodies:
-bind specific targets to cause immune responses to destroy cancer cells
adoptive T-cell transfer:
-isolates and modifies T cells from tumor for enhanced immune response against cancer cell
cytokines:
-role in normal immune response and immune system response to cancer
treatment vaccines:
-enhance immune system response against cancer cells
Bacillus Calmette-Guerin:
-weakened form of TB bacteria, used in bladder cancer to cause immune response against cancer cells
toll-like receptor agonists:
-bind toll-like receptors on immune cells to cause immune response against cancer cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe how IO differs from chemotherapy and targeted therapy.

A

chemotherapy:
-acts directly on cancer cells that are actively reproducing
-often causes tumour cell death vs simply inhibiting tumour growth
targeted therapy:
-inactivates specific proteins in tumour cells that are involved in growth, progression, and spread of cancer
IO:
-triggers the immune system to destroy cancer cells
-considered a type of targeted therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are some inhibitory receptors found on T cells?

A

CTLA-4
PD-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is an example of a CTLA-4 inhibitor?

A

ipilimumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are examples of PD-1 inhibitors?

A

pembrolizumab
nivolumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are examples of PD-L1 inhibitors?

A

durvalumab
atezolizumab
avelumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the site of activity of CTLA-4 inhibitors?

A

lymph node

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the site of activity of PD-1 inhibitors?

A

cancer cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the indications for CTLA-4 inhibitors?

A

melanoma (ipi, ipi + nivo)
kidney cancer (ipi+nivo)
small cell lung cancer (ipi+nivo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

True or false: PD-1 and PD-L1 inhibitors are used for a small range of cancers

A

false
used for a super broad range of cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

True or false: the current IOs are monoclonal antibodies

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How is IO administered?

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is generally done for IO toxicity?

A

doses are NOT reduced for toxicity, either hold or give full dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the response rate to chemotherapy in metastatic melanoma?

A

only 1-2% of pts achieve a durable long-term response to chemotherapy, which is no longer considered as valid treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What was OS for metastatic melanoma prior to introduction of immunotherapy?

Study These Flashcards
A

about 6 months

21
Q

True or false: the response rate to ipilimumab for metastatic melanoma is worse than it was for chemotherapy

Study These Flashcards
A

false
much better survival rates with ipilimumab

22
Q

How was NSCLC once considered as a disease?

Study These Flashcards
A

was once considered a single disease, until distinct subtypes, characteristics identified
-subtype characteristics are clinically relevant for treatment planning from diagnosis

23
Q

What was found with the CheckMate 003 trial?

Study These Flashcards
A

people who responded to the checkpoint inhibitor (nivo) had a long-term durable response vs cytotoxic therapy

24
Q

What was found with the KeyNote-024 trial?

Study These Flashcards
A

pembrolizumab is superior to CT in patients with TPS > 50%

25
Why do different forms of cancer therapies lead to different toxicities?
different MOA leads to different toxicities
26
Which chemotherapy-related and immune-related adverse effects tend to overlap?
NVD fatigue *symptoms may overlap but mediated through different pathways*
27
What happens with irAEs without appropriate management?
irAEs tend to self-perpetuate without appropriate management
28
What are the risk factors for irAEs?
personal/family hx of autoimmune diseases tumor infiltration concomitant medications and occupational exposures
29
What are the key factors for prevention of irAEs?
HCP and patient education -awareness of risks of IO agents patient reporting -immediate reporting of signs and sx call-back program -regular calls to pt to assess irAEs
30
Describe proper irAE follow-up before and after treatment.
during IO treatment: -lab tests before every IO administration -compare values to baseline after IO treatment termination: -lab tests/evaluation on 3 month basis during 1st year and then every 6 months
31
True or false: irAEs can develop even after discontinuation of IO treatment
true
32
What are the potential etiologies of adverse effects?
disease-related incidental event immune-related adverse event
33
Which body systems might be impacted during an irAE via IOs?
skin hepatic gastrointestinal renal eye endocrine cardiac pulmonary neurologic
34
When do the irAEs tend to appear?
rash, pruritis: ~ 4 wks liver: ~6 wks diarrhea, colitis: ~5 wks hypophysitis: ~6 wks
35
Describe the management of irAE according to the severity of symptoms.
grade 1: -supportive care; +/- withhold drug grade 2: -withhold drug, consider restart if toxicity resolves to grade < 1 -initiate low dose steroids (prednisone 0.5 mg/kg/day or ~) if sx do not resolve within 1 week grade 3/4: -d/c drug -high dose steroids (prednisone 1-2 mg/kg/day or ~) taper once grade < 1 severe or steroid-refractory: -no response to steroids within 48-72h -additional immune suppressive agents
36
What do most irAEs resolve with?
temporary or permanent d/c of IO treatment temporary immunosuppression
37
How long does it take for irAEs to resolve?
depends on nature of toxicity -immunosuppression can rapidly improve GI, hepatic, and renal toxicities -skin and endocrine toxicities require more time for resolution
38
What is the impact of immunosuppression on IO efficacy?
no negative impact on treatment efficacy
39
What is the optimal steroid dosing regimen for irAEs?
not yet established -prolonged, high-dose steroid use has been associated with additional risks -confirmed risk of opportunistic infection from steroid use in irAE management
40
Describe proper management of steroid-related complications.
monitor for signs and sx of steroid-related AEs antibiotic prophylaxis may be warranted gradual steroid tapering is important -taper over at least 1 month before resuming IO therapy additional considerations: -vitamin D and calcium (osteoporosis) -PPI (gastritis)
41
What are the toxicities of CAR-T?
B-cell aplasia cytokine release syndrome -frequently begins with fever, may develop unstable hypotension and hypoxia -potentially fatal, may require ICU care neurotoxicity -tremor, dysgraphia, impaired attention, speech difficulty, seizures
42
What is a common complication of both cancer and treatment?
thrombosis -higher mortality among cancer pts -2nd leading cause of death in cancer pts
43
What are the risk factors for cancer-associated thrombosis?
patient related cancer related treatment-related
44
Differentiate when to use LMWH or a DOAC in cancer-associated thrombosis.
LMWH preferred in pts: -at high risk of bleeding -with unresected GI or GU cancer -significant DDI with DOACs DOACs preferred in pts: -at low risk of bleeding -with other cancer types -without significant DDIs
45
How long is duration of therapy for cancer-associated thrombosis?
initial 6 months
46
What is cancer related fatigue?
cancer-related fatigue is a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer tx that is not proportional to recent activity and interferes with usual functioning
47
What is the most commonly reported side effect of cancer treatment with chemotherapy, RT, or selected biologic response modifiers?
cancer related fatigue 14-96% of pts undergoing cancer tx and in 19-82% of pts post-tx
48
What generally occurs to cancer fatigue once treatment is complete?
generally improves but some fatigue may persist for months or years following tx
49
How is cancer related fatigue managed?
manage precipitating factor -rarely an isolated symptom energy conservation exercise with moderate intensity limit naps reduce stress food and water intake use distractions

PHAR359 (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions